Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | SNDX-6352 |
Trade Name | |
Synonyms | SNDX 6352|SNDX6352|UCB6352|Axatilimab |
Drug Descriptions |
Axatilimab (SNDX-6352) is a humanized monoclonal antibody against colony-stimulating factor-1 receptor (CSF-1R), which may enhance anti-tumor immune response (SITC Meeting, Nov 2017, abstract P505). |
DrugClasses | CSF1R Antibody 5 |
CAS Registry Number | 2155851-88-8 |
NCIT ID | C155813 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Durvalumab + SNDX-6352 | Durvalumab SNDX-6352 | 0 | 2 |
Nivolumab + SNDX-6352 | Nivolumab SNDX-6352 | 0 | 1 |
Paclitaxel + Retifanlimab + SNDX-6352 | Paclitaxel Retifanlimab SNDX-6352 | 0 | 1 |
Pembrolizumab + SNDX-6352 | Pembrolizumab SNDX-6352 | 0 | 1 |
SNDX-6352 | SNDX-6352 | 0 | 1 |